Assistant Graduate Director and Associate Professor, Pharmaceutical Sciences
L. Nathan Tumey joined Binghamton University in 2017, following 15 years of experience in the pharmaceutical and biotechnology industry. He received his PhD in chemistry from Duke University in 2001, under the supervision of Michael Pirrung. His research emphasis was on the medicinal chemistry of LpxC inhibitors as antibacterial agents against gram negative bacteria. During his years in the pharmaceutical industry, Tumey was a key leader in multiple drug-discovery programs including the development of 5HT2c agonists for obesity, PKC-theta inhibitors for asthma, IRAK4 inhibitors for rheumatoid arthritis and antibody-drug-conjugates (ADCs) for the treatment of cancer. At Binghamton, his research focuses on the application of antibody-drug conjugates and related modalities for the treatment of auto-immune disorders and rare diseases. Additionally, his lab investigates bioconjugate stability, ADC linker design and new modalities for targeted drug-delivery.
- BS, King University
- PhD, Duke University
- Medicinal chemistry
- Targeted drug delivery
- Antibody-drug conjugates
- Auto-immune disease / inflammation